Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists.
Zhang, X., Belousoff, M.J., Zhao, P., Kooistra, A.J., Truong, T.T., Ang, S.Y., Underwood, C.R., Egebjerg, T., Senel, P., Stewart, G.D., Liang, Y.L., Glukhova, A., Venugopal, H., Christopoulos, A., Furness, S.G.B., Miller, L.J., Reedtz-Runge, S., Langmead, C.J., Gloriam, D.E., Danev, R., Sexton, P.M., Wootten, D.(2020) Mol Cell 80: 485
- PubMed: 33027691 
- DOI: https://doi.org/10.1016/j.molcel.2020.09.020
- Primary Citation of Related Structures:  
6X18, 6X19, 6X1A - PubMed Abstract: 
Peptide drugs targeting class B1 G-protein-coupled receptors (GPCRs) can treat multiple diseases; however, there remains substantial interest in the development of orally delivered non-peptide drugs. Here, we reveal unexpected overlap between signaling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by the non-peptide agonist PF 06882961 and GLP-1 that was not observed for another compound, CHU-128 ...